Edition:
United States

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

15.95USD
18 Jun 2018
Change (% chg)

-- (--)
Prev Close
$15.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
543,506
52-wk High
$27.50
52-wk Low
$7.38

Chart for

About

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company... (more)

Overall

Beta: 2.84
Market Cap(Mil.): $1,593.46
Shares Outstanding(Mil.): 101.49
Dividend: --
Yield (%): --

Financials

  SGMO.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -0.71 -- --
ROI: -31.80 -5.87 13.17
ROE: -37.74 -7.71 15.15

BRIEF-Bioverativ And Sangamo Announce FDA Acceptance Of Ind Application For Gene-Edited Cell Therapy BIVV003

* BIOVERATIV AND SANGAMO ANNOUNCE FDA ACCEPTANCE OF IND APPLICATION FOR GENE-EDITED CELL THERAPY BIVV003 TO TREAT SICKLE CELL DISEASE

May 16 2018

BRIEF-Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23

* SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 08 2018

BRIEF-Sangamo Therapeutics Prices Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Apr 25 2018

BRIEF-Sangamo Therapeutics Proposes Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Apr 24 2018

BRIEF-Sangamo Therapeutics Files For Potential Mixed Shelf Offering

* SANGAMO THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2vH7vVF) Further company coverage:

Apr 24 2018

BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior Executive's Company Email Account

* SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE'S COMPANY EMAIL ACCOUNT

Apr 17 2018

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

Feb 22 2018

UPDATE 2-Sangamo in $3 billion gene-editing deal with Gilead

* Sangamo stock jumps 21 percent (Adds CEO and executive quotes, background, updates share price)

Feb 22 2018

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Feb 22 Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

Feb 22 2018

BRIEF-Sangamo Therapeutics Q4 Loss Per Share $0.15

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Feb 22 2018

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.286.70 -0.80
Pfizer Inc. (PFE.N) $36.16 --
Novartis AG (NOVN.S) CHF75.60 +0.10
Merck & Co., Inc. (MRK.N) $60.99 --
Roche Holding Ltd. (ROG.S) CHF210.80 +0.80
Roche Holding Ltd. (RO.S) CHF215.60 +1.20
Bayer AG (BAYGn.DE) €96.47 -1.99
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €67.57 -0.68
GlaxoSmithKline plc (GSK.L) 1,544.93 -7.87

Earnings vs. Estimates